Kelsey Goodwin
Stock Analyst at Piper Sandler
(4.86)
# 50
Out of 5,182 analysts
38
Total ratings
69.7%
Success rate
61.41%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kelsey Goodwin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RLMD Relmada Therapeutics | Initiates: Overweight | $12 | $6.99 | +71.67% | 1 | Mar 24, 2026 | |
| ERAS Erasca | Maintains: Overweight | $11 → $18 | $17.81 | +1.07% | 3 | Mar 13, 2026 | |
| ACLX Arcellx | Downgrades: Neutral | $120 → $115 | $114.77 | +0.20% | 4 | Feb 26, 2026 | |
| RVMD Revolution Medicines | Maintains: Overweight | $75 → $120 | $99.12 | +21.07% | 2 | Feb 26, 2026 | |
| TNGX Tango Therapeutics | Maintains: Overweight | $11 → $14 | $21.63 | -35.28% | 2 | Jan 16, 2026 | |
| JANX Janux Therapeutics | Maintains: Overweight | $42 → $30 | $14.84 | +102.16% | 2 | Jan 16, 2026 | |
| CGON CG Oncology | Maintains: Overweight | $55 → $70 | $67.48 | +3.73% | 2 | Jan 16, 2026 | |
| BDTX Black Diamond Therapeutics | Maintains: Overweight | $9 → $8 | $2.39 | +234.73% | 2 | Jan 16, 2026 | |
| TARA Protara Therapeutics | Initiates: Overweight | $24 | $5.11 | +369.67% | 1 | Jan 7, 2026 | |
| ORIC ORIC Pharmaceuticals | Initiates: Overweight | $22 | $8.89 | +147.47% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $25 → $26 | $21.45 | +21.21% | 1 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $112 → $128 | $105.43 | +21.41% | 4 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $21 | $19.38 | +8.36% | 1 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $36 | $18.82 | +91.29% | 4 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $36 | $21.47 | +67.68% | 1 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $2.13 | - | 3 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $2.57 | +211.28% | 1 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.07 | - | 1 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $19.14 | - | 1 | Oct 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $3.43 | - | 1 | Oct 31, 2022 |
Relmada Therapeutics
Mar 24, 2026
Initiates: Overweight
Price Target: $12
Current: $6.99
Upside: +71.67%
Erasca
Mar 13, 2026
Maintains: Overweight
Price Target: $11 → $18
Current: $17.81
Upside: +1.07%
Arcellx
Feb 26, 2026
Downgrades: Neutral
Price Target: $120 → $115
Current: $114.77
Upside: +0.20%
Revolution Medicines
Feb 26, 2026
Maintains: Overweight
Price Target: $75 → $120
Current: $99.12
Upside: +21.07%
Tango Therapeutics
Jan 16, 2026
Maintains: Overweight
Price Target: $11 → $14
Current: $21.63
Upside: -35.28%
Janux Therapeutics
Jan 16, 2026
Maintains: Overweight
Price Target: $42 → $30
Current: $14.84
Upside: +102.16%
CG Oncology
Jan 16, 2026
Maintains: Overweight
Price Target: $55 → $70
Current: $67.48
Upside: +3.73%
Black Diamond Therapeutics
Jan 16, 2026
Maintains: Overweight
Price Target: $9 → $8
Current: $2.39
Upside: +234.73%
Protara Therapeutics
Jan 7, 2026
Initiates: Overweight
Price Target: $24
Current: $5.11
Upside: +369.67%
ORIC Pharmaceuticals
Jan 7, 2026
Initiates: Overweight
Price Target: $22
Current: $8.89
Upside: +147.47%
Nov 5, 2025
Maintains: Overweight
Price Target: $25 → $26
Current: $21.45
Upside: +21.21%
Oct 27, 2025
Maintains: Overweight
Price Target: $112 → $128
Current: $105.43
Upside: +21.41%
Aug 19, 2025
Initiates: Neutral
Price Target: $21
Current: $19.38
Upside: +8.36%
Aug 19, 2025
Initiates: Overweight
Price Target: $36
Current: $18.82
Upside: +91.29%
Aug 19, 2025
Initiates: Overweight
Price Target: $36
Current: $21.47
Upside: +67.68%
Mar 28, 2025
Reiterates: Buy
Price Target: n/a
Current: $2.13
Upside: -
Oct 29, 2024
Initiates: Buy
Price Target: $8
Current: $2.57
Upside: +211.28%
Jul 31, 2024
Downgrades: Neutral
Price Target: n/a
Current: $3.07
Upside: -
Oct 31, 2022
Initiates: Neutral
Price Target: n/a
Current: $19.14
Upside: -
Oct 31, 2022
Initiates: Neutral
Price Target: n/a
Current: $3.43
Upside: -